Regulatory CAR-T cells in autoimmune diseases: Progress and current challenges

Area of Science:

• Immunology
• Oncology
• Autoimmune Diseases

Background:

• Chimeric Antigen Receptor (CAR) T-cell therapy has transformed oncology.
• Regulatory T cells (Tregs) show potential for modulating autoimmune diseases.
• Current Treg therapies are limited by polyclonal nature and unknown TCR specificity.

Purpose of the Study:

• To explore the potential of genetically engineered CAR Tregs for autoimmune disease treatment.
• To overcome limitations of current Treg strategies for autoimmune conditions.
• To summarize recent advancements and future perspectives in CAR Treg immunotherapy.

Main Methods:

• Review of recent developments in CAR design.
• Analysis of Treg biology.
• Evaluation of preclinical studies in mouse models.

Main Results:

• Preclinical studies demonstrate immune-modulating properties of CAR Tregs.
• CAR Treg engineering offers antigen-specific targeting for immune modulation.
• Concerns remain regarding CAR target selectivity, function, stability, and safety.

Conclusions:

• CAR Treg immunotherapy presents a promising strategy for autoimmune disease treatment.
• Further research is needed to address safety and efficacy concerns for clinical translation.
• Targeted Treg therapies hold potential for improved autoimmune disease management.